In the U.S., he is called “the raider” but Carl Icahn prefers to be called "activist shareholder" , the same nickname than Edward Lampert, Eric Knight or Guy Wyser-Pratte. Across the Atlantic, he is very popular among small shareholders. In early 2007, Fortune magazine was not afraid of telling about him that if "the shareholders love him, business leaders hate him." According to estimates made by Fortune, the other shareholders of firms where Carl Icahn took in the past a part of the capital would have won, thanks to him, $ 50 billion.
Following an extensive study of the company - no matter the line of businesses- and the evolution of its share price, he takes a minority stake. Afterwards, he contacts the CEO of the company: Carl Icahn is hard-nosed, when he has an idea in mind, he never gives up.
In 2007, he propelled his British rival AstraZeneca to buy the pharmaceutical group US Medimmune. He won an important bonus.
Currently, his portfolio companies are active in the capital of two dozen of U.S companies. Via the Swedish activist fund Cevian, whose he is shareholder, Carl Icahn made his first steps in Europe, for example in the capital of the German Munich Re.
Carl Icahn had, according to Forbes in 2011, a fortune estimated at more than $ 12.5 billion. A success whose he is the only one responsible: coming from a modest family, he studied psychology, then medicine, but it is as broker that he began his career in the sixties. At that time, he had to borrow to start working on the New York Stock Exchange. No doubt he has paid all his bills without late.
At 72 years old, he doesn’t seem determined to retire. He just has launched a new blog : Icahnreport.com.
"You learn in this business: It you want a friend, get a dog."
Copyright © 4-traders.com / Photo © Maxppp